摘要
目的探讨复元醒脑汤对大鼠局灶性脑缺血再灌注损伤的保护作用及其机制。方法将SPF级雄性SD大鼠随机分为假手术组、模型组、复元醒脑汤低、中、高(5.5、11、22g/kg)剂量组。采用线栓法建立大鼠脑缺血再灌注损伤模型,缺血2h再灌注24h,对各组大鼠进行神经功能缺失评分,TTC染色测定脑梗死体积,HE染色观察脑组织病理变化,Nissl染色观察脑组织中尼氏小体的变化,Tunnel染色观察脑组织中神经细胞的凋亡情况。测定血清中的超氧化物歧化酶(SOD)及丙二醛(MDA)的水平。结果与模型组相比,复元醒脑汤低、中、高剂量组均可明显改善大脑中动脉缺血再灌注损伤大鼠的神经行为障碍;TTC染色结果显示,复元醒脑汤低、中、高剂量组大鼠脑梗死体积明显减小;HE结果显示给药组改善脑组织病理结构,Nissl染色结果表明给药组尼氏小体形态数量得到改善,Tunnel染色阳性细胞数减少,细胞凋亡率下降;与模型组相比,复元醒脑汤可提高脑缺血再灌注大鼠血清中SOD的水平,降低MDA水平。结论复元醒脑汤对大鼠大脑脑缺血再灌注损伤具有保护作用。
Objective To study the protective effect of Fu-Yuan-Xing-Nao decoction(FYXND)on rats with middle cerebral ischemia reperfusion injury.Methods Male Sprague-Dawley rats were randomly divided into sham,ischemia-reperfusion,and low,middle,high FYXND dose(5.5,11,22 g/kg)groups.Rats model was induced by 2 hof middle cerebral artery occlusion and 24 hreperfusion.The neurological deficit score of each group was evaluated.The infarct size was measured by the2,3,5-triphenyltetra-zolium(TTC)chloride staining assay.The pathological changes of brain tissue were observed by HE staining assay.The changes of Nissl bodies were observed by Nissl staining.Tunnel staining was used to observe the apoptosis of neurons in brain.Serum levels of superoxide dismutase(SOD)and Malondialdehyde(MDA)were measured.Results Compared with the model group,neurological outcomes were improved in all three groups of low,middle and high FYXND dose(5.5,11,22 g/kg).Significantly reduced infarct brain volume was observed with TTC staining in all three FYXND groups.The results from HE staining assay indicated that the pathological structure of brain tissue was improved in the treatment groups.The numbers and morphology of Nissl corpuscles in the treated group were also improved based on the results of Nissl staining.Both the Tunnel staining positive cells and the rate of apoptosis were decreased.Compared with the model group,FYXND increased the rat serum SOD level and decreased the MDA level.Conclusion FYXND has protective effects on cerebral ischemia reperfusion injury in rats.
作者
李莉
冯晶晶
李铁军
章越凡
LI Li;FENG Jingjing;LI Tiejun;ZHANG Yuefan(School of Pharmacy , Anhui University of Chinese Medicine , Hefei 230012 , China;Department of Pharmacy , Punan Hospital of Pudong New Area , Shanghai 200125 , China;Department of Pharmacology , School of Pharmacy , Second Military Medical University , Shanghai 200433 , China)
出处
《药学实践杂志》
CAS
2018年第1期34-39,共6页
Journal of Pharmaceutical Practice
基金
浦东新区卫生系统重要薄弱学科建设资助(PWZbr2017-16)